FDA policy wades into battles between drug makers and compounders

STAT

mid rising tension between drug makers and compound pharmacies, the Food and Drug Administration has issued new policies ¹ that seek to bolster manufacturing standards for compounded medicines and, in the process, may serve to establish competitive boundaries between